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Abstract
Background: The spine is the most frequent location of bone metastases. Local treatment aims at palliation of pain
and, given the increased likelihood of long-term cancer survival, at local control. Kyphoplasty and intraoperative
radiotherapy (Kypho-IORT) provided instantaneous pain relief in 70% of patients at the first day after the
intervention and resulted in local control rates of > 93% at 1 year in a recently conducted phase I/II trial. To assess
its clinical value, we designed a phase III trial which tests Kypho-IORT against the most widespread standard-of-care,
external beam radiotherapy (EBRT), in patients with painful vertebral metastases.
Methods: This phase III study includes patients ≥50 years of age with up to 4 vertebral metastases and a pain score
of at least 3/10 points on the visual/numeric analogy scale (VAS). Patients randomized into the experimental arm
(A) will undergo Kypho-IORT (Kyphoplasty plus IORT with 8 Gy prescribed to 13 mm depth). Patients randomized
into the control arm (B) will receive EBRT with either 30 Gy in 10 fractions or 8 Gy as a single dose. The primary end
point is pain reduction defined as at least − 3 points on the VAS compared to baseline at day 1. Assuming that 40%
of patients in the Kypho-IORT arm and 5% of patients in the control arm will achieve this reduction and 20% will
drop out, a total of 54 patients will have to be included to reach a power of 0.817 with a two-sided alpha of 0.05.
Secondary endpoints are evaluation of the percentage of patients with a pain reduction of at least 3 points at 2
and 6 weeks, local tumor control, frequency of re-intervention, secondary fractures/sintering, complication rates, skin
toxicity/wound healing, progression-free survival (PFS), overall survival (OS) and quality of life.
Discussion: This trial will generate level 1 evidence on the clinical value of a one-stop procedure which may
provide instantaneous pain relief, long-term control and shortened intervals to further adjuvant (systemic) therapies
in patients with spinal metastases.
Trial registration: Registered with ClinicalTrials.gov, number: NCT02773966 (Registration date: 05/16/2016).
Keywords: Kypho-IORT, Intraoperative radiotherapy, Kyphoplasty, Cement augmentation, Vertebral metastases,
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Background
Due to optimized therapies, life expectancy of
patients with metastasizing cancer will continue to
rise. Bone metastases affect 10–30% of all cancer
patients, especially those located in the vertebral
column. The main clinical problems are severe back
pain and an increased risk of pathological fractures.
Therefore, optimized palliative treatments to improve
quality of life are necessary.
External beam radiotherapy (EBRT) is a well-established
treatment option for patients with spinal metastases.
EBRT results in adequate pain relief with acceptable
local tumor control [1]. Of the retrospective series
that described pain outcome mentioned in the
systematic review by Gerszten et al., roughly 70% of
patients had improvement in pain after radiation
therapy [1]. The mean rate of local control was 77%
(range, 61–89%). Although EBRT is the standard
treatment for painful vertebral metastases, neither the
optimal fractionation schedule nor the optimal stand-
ard dose have been established yet [2].
The two most common schemes are either 10 frac-
tions of 3 Gy (30 Gy total dose) or a single-shot irradi-
ation with 8 Gy [3]. Although EBRT is tolerated well and
local control rates are acceptable, pain relief occurs de-
layed (within weeks) after EBRT, which in the light of
the short life expectancy is unsatisfactory [4]. Based on
data from the Bone Pain Trial [5], one can assume that
as few as 20% of patients will experience pain relief
within the first weeks.
Balloon kyphoplasty is a valuable treatment option for
patients with painful and instable metastases to the ver-
tebral column. In the CAFE trial [6], 134 patients with
vertebral compression fractures were enrolled and ran-
domly assigned to kyphoplasty or non-surgical manage-
ment. The study found that patients treated with
kyphoplasty had a significant reduction of back pain
(from a numeric rating score [NRS] of 7.0 at baseline to
3.5 after kyphoplasty) after seven days.
However, kyphoplasty alone has no documented an-
ticancer effect and thus EBRT is required to avoid
early tumor regrowth. As this may take another 2–4
weeks (due to reduction of single doses to account
for wound healing, e.g. 30Gy in 15 or 40 Gy in 20
fractions), this prolonged treatment poses an un-
acceptable mental and physical challenge to patients.
These considerations also apply for 1times 8Gy, albeit
not that distinct. Moreover, patients with progressive
or simultaneous (e.g. visceral) metastases may also ur-
gently require chemotherapy, which cannot be applied
concurrently to radiotherapy due to the risk of poten-
tiated toxicity.
To reduce treatment time and at the same time increase
quality of life, novel techniques like kyphoplasty combined
with (physical) anticancer methods are required. Our
group developed a novel approach to deliver intraop-
erative radiotherapy during kyphoplasty (Kypho-IORT)
[7–10]. In a recent dose escalation and cohort expan-
sion phase I/II trial we enrolled 61 patients aged 50
years and older with a Karnofsky Performance Status
of at least 60% and with one to three painful verte-
bral metastases confined to the vertebral body [11].
We detected that, after Kypho-IORT, the median pain
score significantly dropped from 5 preoperatively to 2
at the first postoperative day (p < .001) and a persist-
ent pain reduction beyond the first postoperative day
of ≥3 points in 34 (79.1%) patients. As the 3, 6, and
12 month local progression-free-survival (L-PFS) was
excellent with 97.5, 93.8, and 93.8%, we set up this
randomized phase III trial to investigate whether this
new technology may have the potential to replace the
current standard of care.
Methods/design
Study design
This protocol (Version 2.0, April 2016) describes a
prospective, multicenter, randomized phase III study set
up to assess pain reduction after Kypho-IORT (Arm A)
or EBRT (Arm B) for spinal metastases (Fig. 1). Patients
will be recruited over a period of 2.5 years and followed
to a maximum of 5 years.
Objective and primary endpoint
The primary objective of this study is to test if the
analgesic efficiency of Kypho-IORT is superior to
standard-of-care EBRT in patients with painful verte-
bral metastases. The primary end point is to evaluate
the percentages of patients with a pain reduction of
at least 3 points (VAS) at the first post-interventional
day (i.e. one day after Kypho-IORT in Arm A and
one day after the begin of fractionated or single-shot
EBRT in Arm B).
Secondary endpoints
Secondary objectives are
– percentage of patients with a pain reduction of at
least 3 points on VAS at week 2 and 6 weeks after
start of treatment
– local tumor control, measured by longitudinal
CT/MRI scans done at FUs by assigning one of the
following lesion states: stable, osteoradionecrosis,
pathological fracture, sintering progression,
local relapse
– frequency of re-intervention or salvage therapies to
the treated site
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– secondary fractures/sintering progression
– overall progression-free survival
– adverse events
– incidence of cement leakage (including direction of
leakage; symptomatic vs. asymptomatic)
– skin toxicity/wound healing, documented by regular
imaging of the scar
– quality of life, assessed by completion of EORTC
QLQ C30 and BM22 questionnaires
Patient eligibility
Patients ≥50 years of age with up to 4 treatable vertebral
metastases and a localized pain of VAS ≥ 3/10 are eligible
to participate.
Fig. 1 Trial Workflow. *study centers may choose between fractionated EBRT (30 Gy in 10 fractions) or single-dose EBRT (1 × 8 Gy). Once an
option is chosen, the center must adhere to it for all patients included into the trial. Legend: IORT- intraoperative radiotherapy; Kypho-IORT –
kyphoplasty or vertebroplasty + IORT; EBRT – external beam radiotherapy
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Inclusion criteria
 Age ≥ 50 years
 Karnofsky Performance Index ≥60
 initial pain score (VAS) of at least 3 under standard
pain medication (change of the pain medication will
me monitored)
 documented history of cancer (i.e. histological
confirmation of the primary tumor)
 painful osteolytic metastases involving a maximum
of 4 vertebrae of the thoracic/lumbar spine, which
are accessible for Kypho-IORT
 written informed consent
Exclusion criteria
 any prior treatment (irradiation, surgery) of the
target lesion(s)
 Lesions cranial to T3 (T1–2 and cervical spine)
 Tumors infiltrating dorsal vertebral structures
(pedicles, lamina) or intraspinal (epidural) extension
 pathologic fracture with sintering of > 50%
 purely osteoblastic/osteosclerotic metastasis
 high likelihood for cement leakage (e.g. erosions of
the bony borders of the vertebrae), which cannot be
controlled otherwise by operating surgeon
 Pregnancy/lactation
Screening and randomization
After informed consent, all patients will be screened for
inclusion and exclusion criteria and obtain a patient ID.
A baseline visit will then be performed, which includes
the assessment of the KPS and VAS scores, comorbidi-
ties and medication, a gross neurological exam, the
documentation of the underlying primary cancer and the
completion of the QoL questionnaires to obtain base-
lines. If not performed before, a CT or MRI scan of
the spine will have to be performed. After fulfilment
of all inclusion criteria and in the absence of exclu-
sion criteria, patients will then be allocated into any
of the two arms by block randomization (block sizes
of 2 or 4 and stratification by institute). Patients ran-
domized into Arm A will undergo Kypho-IORT, pa-
tients randomized into Arm B will undergo standard
EBRT (10 × 3 Gy or 1 × 8 Gy).
The intervention (Arm A or B) should begin within a
time frame of 14 days after randomization.
Arm a: Kypho-IORT
Kypho-IORT will be carried out under general anaesthe-
sia as extensively described before [8–11]. All patients
will be placed in prone position on a radiolucent table.
An intraoperative low-energy x-ray device (Intrabeam®,
Carl Zeiss Meditec AG, Oberkochen, Germany) will be
used for intraoperative radiotherapy, the centre of the
metastasis shall be chosen for the isocenter of the
radiation.
The cement augmentation can be performed either as
kyphoplasty or in a vertebroplasty technique. Each
patient must receive early post-operative imaging of the
treated vertebra to assess any leakage of cement. The
direction of leakage and the clinical symptoms
associated (symptomatic vs. asymptomatic) must be
documented at this stage.
Arm B: external beam radiotherapy
Patients randomized into arm B will receive conven-
tional external beam radiotherapy, either as fractionated
radiotherapy with 30 Gy delivered in 10 fractions of 3 Gy
or as single-dose irradiation with 8 Gy. Each center must
select and adhere to one treatment option (fractionated
or singe-dose irradiation). Radiotherapy can be given as
per established local standards (3D-conformal radiother-
apy or intensity-modulated radiotherapy, local standards
for target volume and risk organ delineation, local dose
constraints). Patients will need to be seen at least once
weekly by physicians and evaluated for adverse
reactions.
Assessment of efficacy parameters
Pain
Pain will be assessed at baseline (screening) and then at
day 1 (first post-operative day in arm A, first day after
treatment begin in arm B), week 2, and week 6 week
after treatment and at each follow-up visit there will be
an evaluation of pain intensity measured by the visual
analogue scale (VAS) together with the current pain
medication. Any re-intervention or salvage therapies to
the treated site will be also documented.
Local tumor control, progression-free survival
At each follow-up visit (after 6 weeks, 3 months and
thereafter each 6 months), there will be either a MRI or
CT scan of the (complete) spine to determine the re-
sponse of the treated lesion (stable, osteoradionecrosis,
pathological fracture, sintering progression, local relapse)
and to monitor for new metastases to other regions of
the spine (we recommend the same diagnostic routine,
which led to the treatment). Local control is defined as
time span between randomization and local progression.
Local progression is assessed either by serial CT or MRI
scanning. Indicators for local progression in CT scans
are:
– increase in size of osteolytic areas
– development of epidural disease
– progressive sintering/fracture of the treated
vertebral body
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Once progression is suspected in CT scans, a
contrast-enhanced MRI should be performed, whereas
indicators of progression are
– increase in the T2-signal
– epidural disease
It has to be considered that MRI and PET may show
false-positive signals when the time to surgery is less
than 6 months, whereas an epidural disease is the clear-
est indicator. When in doubt the PI and the steering
committee have to decide on the case.
Overall progression-free survival is defined as time
from randomization to any (confirmed) tumor progres-
sion or death by any cause.
Assessment of adverse events
At day 1, week 2, week 6, month 3 and each 6 m
follow-up visit, a physical examination of the surgical
scar /irradiation field will be performed to grade any of
the following toxicities: dermatitis radiation, wound
infection, scar, pigmentation, telangiectasia or other skin
toxicity. In case of any skin toxicities, a photo will be
acquired. A neurological examination will be performed
to detect paresthesia, sensory numbness, motor weak-
ness and paresis. An adverse event (AE) is then defined
as any unfavorable and unintended sign (including an
abnormal laboratory finding), symptom, or disease tem-
porally associated with the use of a medical treatment or
procedure regardless of whether it is considered related
to the medical treatment or procedure (attribution of
unrelated, unlikely, possible, probable, or definite will be
interrogated for at each contact between the responsible
investigator and the study subject until the end of the
study). Ongoing AEs will be followed until recovery.
Wherever possible, adverse events will be reported on
the basis of CTC-AE v4.0.
A pre-existing disease or symptom (including patho-
logical laboratory values) will not be considered an
adverse event unless there will be an untoward change
in its intensity, frequency or quality. This change will be
documented by an investigator.
Serious adverse events (SAE)
Serious adverse events (SAEs) are defined as any event
that is fatal, life threatening, causes or prolongs
hospitalization; causes disability or incapacity or requires
medical intervention to prevent permanent impairment
or damage, or any grade 4 toxicity. Only SAEs that are
judged to be related to surgery or irradiation by the local
study center are reported.
In case of death an autopsy should be done to clarify
the cause of death.
Quality of life
QoL will be determined using the EORTC quality of life
C30 and the bone metastasis module questionnaire
(EORTC-QLQ-C30/BM22). The questionnaires should
be completed before.
treatment and during follow-up visits. The question-
naires have 30 respectively 22 questions and require
approx. 10 min to complete. Even if the patient
progresses or recurs before the last scheduled QoL
assessment, QoL forms should still be completed.
Statistical considerations
Trial sample size
This study is designed to test if the analgesic efficiency
of Kypho-IORT is superior to standard-of-care EBRT in
patients with painful vertebral metastases by comparing
percentages of patients with a pain reduction of at least
3 points on VAS at defined points in time (day 1, week 2
and 6 after start of treatment).
Assuming a pain reduction of VAS-3 points at day one
(first day after Kypho-IORT, one day after the first
EBRT) for 40% of the patients after Kypho-IORT vs 5%
of the patients after EBRT under standard pain medica-
tion (no change of the pretherapeutic pain medication
12 h after Kypho-IORT or 24 h after the first EBRT), the
study will require 22 patients in each arm in order to
have a two-sided alpha of 0.05 and a power of 0.817.
Including a dropout rate of 20% at least 54 patients have
to be recruited. The effect size was estimated on the
basis of the results of the preceded phase I/II trial
[11] and the results of RTOG 9714 [3].
Data analysis
Data will be analysed on an intention to treat basis. All
variables will be described by descriptive statistics
(frequencies, means and standard deviation, medians and
minimum, maximum, depending on data distribution).
The Chi-square test or Fisher’s exact test will be used for
categorical data. For continuous data, parametric or
non-parametric mean comparison tests will be used. The
Kaplan-Meier method with log-rank tests will be used to
estimate relapse-free survival and overall survival.
Ethics and informed consent
The trial will be carried out in compliance with the
protocol, the principles laid down in the declaration of
Helsinki, version as of October 1996 (as long as local
laws do not require to follow other versions), in accord-
ance with the ICH Harmonised Tripartite Guideline for
Good Clinical Practice (GCP), the harmonized standards
for Medical Devices (ISO 14155) and all other applicable
regulatory requirements (local, regional and global).
Standard medical care (prophylactic, diagnostic and
therapeutic procedures) remains in the responsibility of
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the treating physician of the patient. This study was ap-
proved by the local ethics committee (Medical Ethics
Commission II of the Faculty of Medicine Mannheim,
University of Heidelberg, 2013-593 N-MA) and the
Federal Office of Radiation Protection (Z5–22462/2–
2013-116). All patients participating in the study need to
provide written informed consent at least 24 h prior to
the intervention.
Trial registration
The trial is registered with ClinicalTrials.gov, number
NCT02773966.
Discontinuation of the trial
Individual withdrawal
Treatment of the patient must be discontinued if one or
more of the following criteria apply:
– revocation of the patient’s declaration of informed
consent
– lack of compliance
– discontinuation of the therapy for other reasons
deemed necessary by the responsible physician
(e.g. unfavorable intraoperative geometry)
– Grade IV skin toxicity, i.e. skin necrosis that require
surgical intervention
– Grade IV bone toxicity, i.e. aseptic bone necrosis
that require surgical intervention
– Grade IV nervous system toxicity, i.e. paresis
When therapy is discontinued, the reasons for discon-
tinuing patient participation in the study must be listed
in the patient’s file.
Investigator withdrawal
The steering committee is allowed to close the study
ahead of schedule.
Other termination criteria include:
– insufficient patient recruitment
– unexpectedly severe toxicities (second Grade IV
toxicity within the study)
– unexpected findings which prevent the continuation
of the study for ethical and/or medical reasons
(new benefit/risk analysis)
Discussion
Kypho-IORT is a technically feasible new treatment op-
tion that provided immediate pain relief, structural stabil-
ity and excellent local tumor control without severe side
effects in a phase I/II trial [11]. As the potential benefit of
this one-stop-procedure is still unclear in comparison to
the gold standard (usually 30Gy in 10 fractions in Euro-
pean countries, 8 Gy single shot in the US), we designed
the randomized trial introduced here. The primary end-
point of this trial is pain reduction immediately at day 1
after treatment (one day after Kypho-IORT or one day
after the first/only session of EBRT, respectively). We be-
lieve that immediate pain control is a key expectation for
the vast majority of patients that are referred to radiation
oncology for palliation of pain.
EBRT is an integral part of local therapy, but, as seen
in several studies pain control is achieved in weeks (or
even months) [12]. In the initial phase I/II trial, 70% of
patients that had a preoperative pain score of ≥3 re-
ported a reduction of 3 or more points at the first post-
operative day [11]. The trial presented here will thus
now evaluate whether this procedure may prospectively
be offered as an (potentially superior) alternative to
standard external-beam radiotherapy.
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